Clinical trial NCT03402737: SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N
Official title: Combined Hypofractionated Stereotactic Body Radiotherapy With Immunomodulating Systemic Therapy for Inoperable Recurrent Head and Neck Cancer: Detection of the Maximum Tolerated Dose.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Head and Neck Neoplasm
Keywords: Stereotactic body radiotherapy
Immunomodulating systemic therapy
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2018-01-18
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: The range of dose-painting will be escalated in following levels:

* 2x 6-8Gy
* 3x 6-8Gy

The standard "3+3" design will be used for the this trial. To obtain more precise toxicity rate of the MTD we will double the number of patients at the first dose prescription that gives totally 6 patients. The 3 remaining dose levels will include 3 patients each. Thus, fifteen (6+3+3+3) patients will be included in this radiotherapy dose finding study investigating the MTD.

The number of patients will be doubled in case of 2 DLTs at the dose prescription I and 1 DLT at dose prescriptions II-IV with DLT in a maximum of 10 out of 30 patients.

* 3x 6-10Gy
* 3x 6-12Gy
Primary purpose: TREATMENT

Brief summary: To derive the maximum tolerated dose of hypofractionated stereotactic body radiotherapy (SBRT) using dose painting by numbers with immunomodulating systemic therapy in patients that are reirradiated for recurrent squamous cell carcinoma of the head and neck.

Detailed description: The standard treatment in inoperable locally or regionally recurrent head and neck cancer has long been palliative systemic therapy using the so-called EXTREME-scheme: a combination of cisplatin, 5-fluorouracil and cetuximab. This therapy remains without realistic chances of cure. More recently, immunotherapy using nivolumab has demonstrated to result in long-term disease control of 1-2 year in cisplatin-refractory recurrent or metastatic head and neck cancer, however only in a small portion of patients (13%).

Fractionated high-dose local or regional re-irradiation is mostly given in a 6-7 weeks scheme. Using stereotactic body radiotherapy (SBRT), high radiotherapy doses can be given in a short time span. Severe late adverse events have been reported using SBRT but seem less frequent than in patients re-treated with conventional schedules. A possible solution to be able to administer higher doses is combining SBRT with dose painting, thus giving these high doses on small subvolumes only.

Addition of concomitant therapy to reirradiation may further improve outcomes due to radiosensitization and direct cytotoxicity. Therefore the investigator aims to combine high doses with concomitant therapy in the proposed study.

The immunomodulatory effect caused by radiation has been demonstrated both in animal models and clinical trials and leads to an enhanced local control as well as to eradication of distant metastasis. This so-called abscopal effect is reached through a systemic immune response evoked by the release of damage-associated molecular patterns (DAMPs) by the dying tumor-cells, also called immunogenic cell death (ICD).

The investigator hypothesizes that an abscopal effect could be present for patients presenting locoregional recurrent disease with asymptomatic distant metastases, thereby offering at least symptom control at the primary site while palliative systemic treatment could be postponed.

The proposed protocol focuses on patients with bad prognosis, as determined by a short timespan between primary therapy and recurrence (defined as 6-24 months after the end of the primary radiotherapy). It would bring the practical advantage of only 2-3 patient visits for the radiotherapy instead of ± 30-35 visits over 6-7 weeks. This shorter treatment schedule is expected to result in a direct gain in quality-of-life due to locoregional symptom control. It can also be expected that rescue systemic therapy will be postponed to a later stage of disease development, thereby prolonging overall survival.

The combination with systemic agents that are involved in immunogenic cell death bear the potential to result in a higher number of patients with longer periods of disease control and survival. The current standard of care, i.e. the combined systemic treatment with cisplatin - 5-fluorouracil - cetuximab, or nivolumab in case of former cisplatin use, can be used as a rescue regimen in case of therapy failure. In that sense, better overall survival from time of diagnosis of the index locoregional recurrent disease is expected.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx or cancer of unknown primary (CUP) in the neck in previously irradiated tissue, with former irradiation with curative intent.
* Patients with non-symptomatic distant metastases and local, regional or combined locoregional recurrence can be included.
* In case of non-metastatic disease, the recurrence must be primarily unresectable recurrence and/or patients refused surgery.
* Time interval 6-24 months after the end of the initial radio(chemo)therapy for primary head and neck cancer.
* Decision of the Head and Neck Tumor Boards at the recruiting centre to offer salvage radio(chemo)therapy, palliative chemotherapy or anti-PD-1 antibody treatment with nivolumab for cisplatin-refractory locoregional recurrent head and neck squamous cell carcinoma.
* Karnofsky performance status ≥ 70.
* Age ≥ 18 years old.
* Informed consent obtained, signed and dated before specific protocol procedures.

Exclusion Criteria:

* Previous radiotherapy was for cT1-2 cN0 M0 glottic cancer.
* Grade ≥ 4 late toxicity after the initial radio(chemo)therapy.
* Brachytherapy as treatment for second primary / recurrence.
* Previous (combination with) immunotherapy for the primary or the recurrent squamous cell carcinoma.
* Impossibility of oral intake of cyclophosphamide.
* For patients receiving cyclophosphamide: necessary intake during therapy of allopurinol, amiodarone, digoxin, hydrochlorothiazide, indomethacin, phenobarbital, phenytoin, warfarin. clopidogrel, ticlopidine, carbamazepine, efavirenz, rifampicin, ritonavir
* High risk for arterial blow-out: 1 of following criteria is sufficient to exclude patients:

  1. soft tissue necrosis
  2. skin invasion of the recurrent cancer
  3. circumferential involvement of \> 180° of a carotid artery
* Symptomatic distant metastases.
* Other uncontrolled second primary tumors.
* Pregnant or lactating women.
* Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
* Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.

Primary outcomes:
measure: maximum tolerated dose
timeFrame: 3 months after radiotherapy
Secondary outcomes:
measure: symptom palliation - pain
timeFrame: through study completion, an average of 12 months
measure: symptom palliation - dysphagia
timeFrame: through study completion, an average of 12 months
measure: local control
timeFrame: 3 months after SBRT and thereafter through study completion, an average of 12 months
measure: Overall survival
timeFrame: through study completion, an average of 12 months
measure: Progression free survival
timeFrame: through study completion, an average of 12 months
measure: grade ≥ 3 toxicity-free survival
timeFrame: through study completion, an average of 12 months
measure: QOL - general
timeFrame: before therapy, week 3, week 6, week 10, week 14
measure: QOL - H&N specific
timeFrame: before therapy, week 3, week 6, week 10, week 14
measure: topographic distribution of recurrence
timeFrame: through study completion, an average of 12 months
measure: time to further treatment
timeFrame: through study completion, an average of 12 months
measure: immune response
timeFrame: using serum taken before treatment and at each fraction of SBRT, at weeks 6-14
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: Radiotherapy department, University Hospital Ghent
state: Oost-Vlaanderen
city: Leuven
country: Belgium
facility: UZ Leuven
city: Namur
country: Belgium
facility: CHU Namur
Study officials:
affiliation: Gent University
name: Fréderic Duprez, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: